Phase I trial of weekly and every 3 weeks ixabepilone (Ix) and sunitinib (S) in advanced solid tumors (STs).

@article{Kittaneh2011PhaseIT,
  title={Phase I trial of weekly and every 3 weeks ixabepilone (Ix) and sunitinib (S) in advanced solid tumors (STs).},
  author={M. Kittaneh and A. Montero and K. Kov{\'a}cs and V. D. Guardiola Amado and A. Flores and A. Ferrell and M. Vulfovich and M. Pegram and P. Benedetto and C. R. Rocha Lima and J. Merchan},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={3081}
}
  • M. Kittaneh, A. Montero, +8 authors J. Merchan
  • Published 2011
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 3081 Background: Ix is a cytotoxic microtubule-stabilizing agent with anti-proliferative and anti-angiogenic properties. S is a multi-targeted receptor tyrosine kinase inhibitor. IX and S combination may be synergistic, since S may increase delivery of Ix to the tumor by inducing vascular normalization. METHODS Patients (pts) with advanced STs were enrolled in a phase I, dose-escalation study to assess safety, pharmacokinetics (PK), angiogenesis biomarkers and to determine the recommended… CONTINUE READING
    1 Citations
    Profile and potential of ixabepilone in the treatment of pancreatic cancer
    • 8
    • PDF